VANCOUVER, British Columbia, Aug. 14, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 AI Labs, Inc. (OTC: FITY), a leader in AI-powered drug repurposing and precision medicine, today announced the completion of the largest and most comprehensive study of Sickle Cell Disease (SCD) ever undertaken. Leveraging a decade's worth of real-world patient data, the study mapped disease progression and treatment outcomes at an unprecedented scale—marking a major milestone in the fight against this life-threatening genetic ...